Navigation Links
Boston Scientific Announces Results For Second Quarter Ended June 30, 2013
Date:7/25/2013

NATICK, Mass., July 25, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $1.809 billion and adjusted earnings per share of $0.18 for the second quarter ended June 30, 2013.  The company reported GAAP earnings of $0.10 per share.

Second quarter results and recent developments:

  • Exceeded high end of the guidance range with sales of $1.809 billion -- a year-over-year decline of 1 percent on a reported basis and operational growth of 2 percent (constant currency basis, excluding divested businesses). 
  • Delivered adjusted EPS of $0.18, exceeding the company's adjusted EPS guidance range of $0.14 to $0.17.
  • Achieved global year-over-year revenue growth of 21 percent in Neuromodulation on the strength of the Precision Spectra™ Spinal Cord Stimulator (SCS) System launch, 8 percent in Endoscopy and 5 percent in Peripheral Interventions, all on a constant currency basis.
  • Continued global expansion with combined year-over-year growth of 29 percent in Brazil, Russia, India and China, all on a constant currency basis.
  • Reported positive clinical data related to the Vessix Renal Denervation System, WATCHMAN® Left Atrial Appendage Closure Device, Lotus Aortic Valve System and Vercise Deep Brain Stimulation System - technologies the company believes will help drive growth.
  • Entered into a definitive agreement to acquire the electrophysiology (EP) business of C.R. Bard, Inc., for $275 million in cash. 
  • Generated operating cash flow of $396 million and used $100 million to repurchase approximately 12.5 million shares under the company's existing share repurchase authorizations.
  • "We are pleased with our improved performance during the quarter," said Mike Mahoney, president and chief executive officer, B
    '/>"/>

    SOURCE Boston Scientific Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related biology technology :

    1. American Laboratory Trading Continues Steady Growth with Expansion in Boston
    2. Affordable Scrum Training in Boston,MA by Conscires Agile Practices
    3. Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston
    4. The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA
    5. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
    6. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
    7. Local Leaders Convene in Boston to Share Industry Best Practices in Second “Business of Big Data” Summit
    8. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
    9. Boston College researchers unique nanostructure produces novel plasmonic halos
    10. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2012 Financial Results on January 29th
    11. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/25/2015)... , March 25, 2015  S&P Capital ... Factual Stock Report coverage on Abattis Bioceuticals ... ATTBF; CSE: ATT): is a specialty biotechnology company ... cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, ... in North America . The ...
    (Date:3/25/2015)... -- Accelovance, a therapeutically focused contract research organization (CRO), ... Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards ... This is the eighth consecutive year Accelovance has been ... "Best Contract Research Organization" in 2009, 2010, and 2011, ... "We,re excited to be a finalist for the ...
    (Date:3/25/2015)... An increase of awareness related to benefits of ... nutrients, regulatory changes and concerns related to consumer safety ... natural astaxanthin over the past few years. Producers of ... to satisfy the rising demand. , The global ... in nutraceuticals, aqua feed, food and beverages and cosmetics) ...
    (Date:3/25/2015)... South San Francisco, CA (PRWEB) March 25, 2015 ... Trial Provide Support for Novel Mechanism of Action ... CA, March 25, 2015 – Cytokinetics, Incorporated (Nasdaq: ... to its fast skeletal muscle troponin activator tirasemtiv ... results from a Phase IIa “Evidence of Effect” ...
    Breaking Biology Technology:S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
    ... , Multiporator / Electroporator 2510 , , , , , , ... , Protocol No. 4308 915.513 04/2002 , , ... , , Microorganism , ... Cell type , Bacteria, gram negative, , ...
    ... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.506 12/2001 ... , , , , , ... , Cell type , ...
    ... , , , , , , Multiporator / Electroporator 2510 , , ... , Transformation Protocol , Protocol No. 4308 ... , , , , , , ... , , Cell type , ...
    Cached Biology Technology:Escherichia coli DH10B 2Escherichia coli DH10B 3Borrelia burgdorferi 2Agrobacterium tumefaciens 2
    (Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
    (Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report to ... for Hand Geometry in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and ...
    (Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
    Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
    ... Health Organization (WHO) and the United Nations Children's Fund (UNICEF) ... from measles, a leading vaccine-preventable killer, by the end of ... 873 000 in 1999 to an estimated 530 000 in ... with the highest burden of the disease, where estimated measles ...
    ... Chemistry Professor John T. Fourkas have demonstrated that ... can be induced to emit light so strongly ... single nanoparticle. Fourkas, in collaboration with postdoctoral researcher ... Vincent Chen, coaxed the particles into strong emission ...
    ... us, our mind's eye has a bias. For reasons that ... tendency to devote more visual attention to the left side ... known as pseudoneglect. Researchers now report that pseudoneglect is not ... only that brain structures thought to play a requisite role ...
    Cached Biology News:Measles Deaths Worldwide Drop By Nearly 40% Over Five Years 2Findings have implications for tracking disease, drugs at the molecular level 2The lopsided brain: Attention bias is shared by humans and birds 2
    ...
    Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
    ... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
    ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
    Biology Products: